Patent EP0158564B1 successfully refreshed from Google Patents.
EP0158564B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Expression vectors for hirudin, transformed cells and process for the preparation of hirudin
Assignee: Bayer Pharma AG
•
Filing: 1985-03-27
•
Granted: 1992-07-15
•
Expires: 2005-03-27
Abstract
Abstract Vector for the cloning and expression in a host cell of hirudine or an analogue of hirudine, characterized in that it comprises the gene coding for hirudine or an analogue of hirudine, and the elements for the expression of this gene in said host cell, said coding gene beginning, after the starting sequence, by an ile codon and a thr codon.
Inventors
- 👤 Paul Tolstoshev
- 👤 Richard Harvey
- 👤 Michael Courtney
- 👤 Jean-Pierre Lecocq
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 16:08
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/81; C07K14/815; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/70; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
18 words
Hirudin containing all or part of the following peptide: as well as its variant: 1. Ile-Val 2. Thr-Val
Claim 2
Dependent Claim
18 words
Hirudin containing all or part of the following peptide: as well as its variant: 1. Ile-Val 2. Thr-Val
Claim 3
Dependent Claim
16 words
Hirudin as claimed in claim 1, characterized in that it does not comprise glycosylation or sulfatation.
Claim 4
Dependent Claim
45 words
Vector for cloning and expression of hirudin or a hirudin analog in a host cell, characterized in that it contains the gene coding for hirudin or a hirudin analog said coding gene begining with a sequence coding, after the starting sequence, for Ile and Thr.
Claim 5
Dependent Claim
45 words
Vector for cloning and expression of hirudin or a hirudin analog in a host cell, characterized in that it contains the gene coding for hirudin or a hirudin analog said coding gene begining with a sequence coding, after the starting sequence, for Ile and Thr.
Claim 6
Dependent Claim
21 words
Vector as claimed in claim 3, characterized in that it contains the following sequence at the start of the hirudin gene:
Claim 7
Dependent Claim
21 words
Vector as claimed in claim 4, characterized in that it contains the following sequence at the start of the hirudin gene:
Claim 8
Dependent Claim
18 words
Vector pTG 720 deposited in the strain E. coli TGE 900 at the CNCM under the n° I-428.
Claim 9
Dependent Claim
18 words
Vector pTG 720 deposited in the strain E. coli TGE 900 at the CNCM under the n° I-428.
Claim 10
Dependent Claim
14 words
Cell transformed by a vector as claimed in one of claims 3 to 6.
Claim 11
Dependent Claim
13 words
Cell as claimed in claim 7, characterized in that it is a bacterium.
Claim 12
Dependent Claim
16 words
Cell as claimed in claim 8, characterized in that it is a strain of E. coli.
Claim 13
Dependent Claim
37 words
Process for the preparation of hirudin or a hirudin analog, characterized in that a transformed cell as claimed in one of claims 7 to 9 is cultured and wherein the hirudin or hirudin analog formed is recovered.
Claim 14
Dependent Claim
44 words
Process as claimed in claim 10, characterized in that the hirudin is recovered from the culture product by heating at acid pH followed by decantation, the hirudin or its analog being recovered by decantation, the hirudin or its analog being recovered in the supernatant.
Claim 15
Dependent Claim
37 words
Process as claimed in either of claims 10 and 11, characterized in that the hirudin is recovered by binding it to a resin bearing thrombin, followed by elution of the resin after binding with a hirudin competitor.
Claim 16
Dependent Claim
19 words
Hirudin or hirudin analog obtained by carrying out the process as claimed in one of claims 10 to 12.
Claim 17
Dependent Claim
31 words
Use of hirudin as claimed in one of claims 1 and 2 and 13 which is labeled for manufacturing an agent for the diagnosis of clot formation in man or animals.
Claim 18
Dependent Claim
30 words
Extracorporeal blood circuit, wherein at least part of the circuit in contact with the blood is coated with hirudin as claimed in one of claims 1 and 2 and 13.
Claim 19
Dependent Claim
38 words
Process for the separation of a clotting factor from blood or from a blood fraction, characterized in that said separation is performed, in the presence of hiruding as claimed in one of claims 1 and 2 and 13.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.